Unicycive (UNCY) narrows 2025 loss, FDA accepts kidney drug NDA resubmission
Rhea-AI Filing Summary
Unicycive Therapeutics reported narrower losses for the year ended December 31, 2025 and highlighted regulatory progress for its lead kidney-disease drug candidate. Research and development spending fell to $9.1 million from $20.0 million as major clinical work wound down, while general and administrative costs rose to $20.4 million from $12.1 million due to consulting, professional services, and commercial launch preparation.
Net loss attributable to common stockholders improved to $26.6 million, or $1.67 per share, from $37.8 million, or $5.65 per share, helped by lower R&D and a favorable warrant liability revaluation that turned other income to $3.0 million from a $4.6 million expense. As of March 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, and the company states it can fund planned operations into 2027. Management noted that the FDA has accepted its New Drug Application resubmission for oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients, with the potential for approval and launch later in 2026.
Positive
- FDA accepted NDA resubmission for OLC, with stated potential for approval and launch later in 2026 for hyperphosphatemia in dialysis patients, marking a key late-stage regulatory milestone.
- Net loss attributable to common stockholders narrowed to $26.6 million from $37.8 million year over year, helped by a sharp reduction in research and development expenses and favorable warrant liability revaluation.
- Liquidity appears solid with unaudited cash, cash equivalents, and marketable securities of $54.9 million as of March 30, 2026, and the company stating it can fund planned operations into 2027.
Negative
- General and administrative expenses increased materially to $20.4 million from $12.1 million year over year, reflecting higher consulting, professional services, and commercial launch preparation costs while the company remains loss-making.
Insights
NDA resubmission progress and improved loss profile, but spending shifts toward commercialization.
Unicycive Therapeutics reported a 2025 net loss of $26.6 million, substantially better than $37.8 million in 2024, mainly because research and development expenses dropped to $9.1 million from $20.0 million. This reflects reduced drug development and clinical trial activity as its lead asset moves further along the regulatory path.
At the same time, general and administrative costs rose to $20.4 million from $12.1 million, driven by consulting, professional services, and commercial launch preparation. Other income swung to a $3.0 million gain from a $4.6 million loss, largely from changes in warrant liability fair value.
Unaudited cash, cash equivalents, and marketable securities of $54.9 million as of March 30, 2026 are described as sufficient to fund planned operations into 2027, important as the FDA has accepted the New Drug Application resubmission for oxylanthanum carbonate with potential approval and launch later in 2026. Future company updates may clarify regulatory timelines and commercialization plans for OLC and development progress for UNI-494.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (Commission File Number) | IRS Employer | ||
| incorporation or organization) | Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
| Item 2.02 | Results of Operations and Financial Conditions. |
On March 30, 2026, Unicycive Therapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a business update. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
| 99.1 | Press Release of Unicycive Therapeutics, Inc. dated March 30, 2026. | |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: March 30, 2026
| UNICYCIVE THERAPEUTICS, INC. | ||
| By: | /s/ Shalabh Gupta | |
| Shalabh Gupta | ||
| Chief Executive Officer | ||
2
Exhibit 99.1
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
| - | Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 |
| - | Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26 |
| - | As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 |
LOS ALTOS, Calif., March 30, 2026 -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update.
“This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration’s acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With hyperphosphatemia still uncontrolled in nearly 75% of U.S. patients with chronic kidney disease undergoing dialysis, OLC, if approved, has the potential to offer a meaningful new treatment option characterized by a differentiated clinical profile and reduced pill burden compared to currently available phosphate binders.”
Key Highlights & Upcoming Milestones
| ● | In January 2026, the Company announced the FDA has accepted the resubmission of its NDA for OLC, an investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with CKD on dialysis. The FDA set a PDUFA target action date of June 29, 2026. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers and a tolerability study in patients with CKD on dialysis), multiple preclinical studies and chemistry, manufacturing and controls (CMC) data. The FDA did not raise any concerns regarding the preclinical, clinical or safety data for OLC included in the original NDA submission. The resubmission in December 2025 was based on the progress made by the third-party manufacturing vendor responsible for the drug product (Drug Product). |
| ● | As part of Unicycive’s continued preparation to support a potential launch of OLC later this year, the Company is continuing to strengthen its commercial infrastructure and advance market readiness initiatives. |
Financial Results for the Year Ended December 31, 2025
Research and Development (R&D) expenses were $9.1 million for the year ended December 31, 2025, compared to $20.0 million for the same period in 2024. The decrease in research and development expenses was primarily due to a decrease in drug development as well as clinical trial costs.
General and Administrative (G&A) expenses were $20.4 million for the year ended December 31, 2025, compared to $12.1 million for the same period in 2024. The increase was primarily due to an increase in consulting, professional services, and commercial launch preparation costs.
Other income was $3.0 million for the year ended December 31, 2025 compared to Other expense of $4.6 million in the same period in 2024 due primarily to a decrease in the fair value of the Company’s warrant liability.
Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024. The decreased net loss for the year ended December 31, 2025, was attributable primarily to the decrease in drug development and clinical trial costs.
As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million. The Company believes that it has sufficient resources to fund planned operations into 2027.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; our dependence on third parties for manufacturing; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of our products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
2
Unicycive Therapeutics, Inc.
Balance Sheets
(in thousands, except for share and per share amounts)
| As of | As of | |||||||
| December 31, | December 31, | |||||||
| 2024 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 26,142 | $ | 29,198 | ||||
| Prepaid expenses and other current assets | 4,806 | 7,692 | ||||||
| Marketable securities | - | 12,071 | ||||||
| Total current assets | 30,948 | 48,961 | ||||||
| Right of use asset, net | 645 | 108 | ||||||
| Property and equipment, net | 75 | 66 | ||||||
| Total assets | $ | 31,668 | $ | 49,135 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,058 | $ | 383 | ||||
| Accrued liabilities | 3,562 | 1,523 | ||||||
| Warrant liability | 18,936 | 16,915 | ||||||
| Operating lease liability - current | 564 | 117 | ||||||
| Total current liabilities | 24,120 | 18,938 | ||||||
| Operating lease liability - long term | 117 | - | ||||||
| Total liabilities | 24,237 | 18,938 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Series A-2 Prime preferred stock, $0.001 par value per share - 21,388.01 Series A-2 Prime shares authorized at December 31, 2024, and December 31, 2025; 6,150.21 and 2,265 Series A-2 Prime shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | - | - | ||||||
| Series B-2 preferred stock, $0.001 par value per share - 50,000 Series B-2 shares authorized at December 31, 2024, and December 31, 2025; 3,000 and zero Series B-2 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | - | - | ||||||
| Preferred stock, $0.001 par value per share- 10,000,000 shares authorized at December 31, 2024, and December 30, 2025; zero shares issued and outstanding at December 31, 2024, and December 31, 2025 | - | - | ||||||
| Common stock, $0.001 par value per share - 400,000,000 shares authorized at December 31, 2024, and December 31, 2025; 11,384,236 and 22,114,245 shares issued and outstanding at December 31, 2024, and December 31, 2025, respectively | 11 | 22 | ||||||
| Accumulated other comprehensive loss | - | (1 | ) | |||||
| Additional paid-in capital | 108,690 | 158,001 | ||||||
| Accumulated deficit | (101,270 | ) | (127,825 | ) | ||||
| Total stockholders’ equity | 7,431 | 30,197 | ||||||
| Total liabilities and stockholders’ equity | $ | 31,668 | $ | 49,135 | ||||
3
Unicycive Therapeutics, Inc.
Statements of Operations
(in thousands, except for share and per share amounts)
| Year Ended | Year Ended | |||||||
| December 31, | December 31, | |||||||
| 2024 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 20,014 | $ | 9,121 | ||||
| General and administrative | 12,103 | 20,396 | ||||||
| Total operating expenses | 32,117 | 29,517 | ||||||
| Loss from operations | (32,117 | ) | (29,517 | ) | ||||
| Other income (expenses): | ||||||||
| Interest income | 1,261 | 1,012 | ||||||
| Interest expense | (71 | ) | (71 | ) | ||||
| Change in fair value of warrant liability | (5,802 | ) | 2,021 | |||||
| Total other income (expenses) | (4,612 | ) | 2,962 | |||||
| Net loss | (36,729 | ) | (26,555 | ) | ||||
| Other comprehensive loss: | ||||||||
| Unrealized loss on marketable securities, net | - | (1 | ) | |||||
| Net comprehensive loss | $ | (36,729 | ) | $ | (26,556 | ) | ||
| Dividend to Series B-1 preferred stockholders | (1,095 | ) | - | |||||
| Net loss attributable to common stockholders | $ | (37,824 | ) | $ | (26,555 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (5.65 | ) | $ | (1.67 | ) | ||
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 6,698,513 | 15,886,876 | ||||||
4
FAQ
How did Unicycive (UNCY) perform financially in full-year 2025?
What were Unicycive (UNCY) research and development and G&A expenses for 2025?
What is the status of Unicycive’s lead drug candidate oxylanthanum carbonate (OLC)?
How much cash does Unicycive (UNCY) have and how long is its runway?
How did warrant liability changes affect Unicycive’s 2025 results?
What pipeline assets beyond OLC does Unicycive (UNCY) highlight?
Filing Exhibits & Attachments
4 documents